Greenwich LifeSciences (GLSI)
(Delayed Data from NSDQ)
$15.29 USD
+0.68 (4.65%)
Updated Sep 24, 2024 03:59 PM ET
After-Market: $15.29 0.00 (0.00%) 7:46 PM ET
4-Sell of 5 4
D Value B Growth D Momentum C VGM
Brokerage Reports
0 items in cart
Greenwich LifeSciences, Inc. [GLSI]
Reports for Purchase
Showing records 1 - 17 ( 17 total )
Company: Greenwich LifeSciences, Inc.
Industry: Medical - Biomedical and Genetics
2Q24 Financial Results Reported; Reiterate Buy; Modulating PT to $38
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Greenwich LifeSciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Greenwich LifeSciences, Inc.
Industry: Medical - Biomedical and Genetics
Phase 3 Trial Approved to Expand into Five European Countries; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Greenwich LifeSciences, Inc.
Industry: Medical - Biomedical and Genetics
Phase 3 Trial Protocol Accepted by European Regulators; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Greenwich LifeSciences, Inc.
Industry: Medical - Biomedical and Genetics
Phase 3 Breast Cancer Trial Progress On Track; Reiterate Buy; Adjusting PT Down to $36
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Greenwich LifeSciences, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for GLSI 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Greenwich LifeSciences, Inc.
Industry: Medical - Biomedical and Genetics
2022 Financial Results Reported; Reiterate Buy; Lowering PT to $38
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Greenwich LifeSciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Greenwich LifeSciences, Inc.
Industry: Medical - Biomedical and Genetics
Phase 3 Breast Cancer Trial Begins Patient Screening; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Greenwich LifeSciences, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Hold Removed; Phase 3 Breast Cancer Trial Proceeds; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Greenwich LifeSciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Results; Phase 3 Breast Cancer Trial May Start Soon; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Greenwich LifeSciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Greenwich LifeSciences, Inc.
Industry: Medical - Biomedical and Genetics
Commercial Line Filling of GP2 Commences; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Greenwich LifeSciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Greenwich LifeSciences, Inc.
Industry: Medical - Biomedical and Genetics
Pivotal Phase 3 Trial to Commence Soon; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Greenwich LifeSciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Greenwich LifeSciences, Inc.
Industry: Medical - Biomedical and Genetics
Preventing Breast Cancer Recurrence; Initiating at Buy and $78 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
|